STRUGGLE FOR. Włosko-polsko-hiszpańsko-uzbecko-wietnamskie Stanowisko Ekspertów 2023 dotyczące lepszej kontroli klasycznych modyfikowalnych czynników ryzyka w praktyce klinicznej

The progress in pharmacotherapy that has been made in recent years, including the introduction of very effective and safe lipid-lowering and antihypertensive drugs, has not yet translated into the expected universal control of blood pressure, lipid disorders and diabetes. In STRUGGLE FOR Italian-Polish-Spanish-Uzbek-Vietnamese Expert Forum Position Paper 2023, experts from five countries recalled in several points the paradigms of cardiological and cardiometabolic care for better control of classical modifiable risk factors in the year 2023. We believe that the need to intensify treatment, actively search for patients with cardiovascular risk factors, especially with arterial hypertension, hypercholesterolemia and diabetes, should go hand in hand with the implementation of the latest therapy, based on single pill combinations (SPCs) including proven, effective antihypertensive, lipid-lowering and antidiabetic molecules, many of which we have listed in our document. We need to use both new technological concepts, completely new drugs, as well as novel treatment concepts such as metabolic treatment in coronary artery disease, try to intensify the fight against smoking in every way, including the available range of drugs and procedures reducing the harm. This approach will give us substantially better control of the underlying cardiovascular risk factors in countries as different as Italy, Poland, Spain, Uzbekistan and Vietnam.

Перевод пока недоступен